NCT03672539 - Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER